Advertisement
Canada markets close in 6 hours 3 minutes

  • S&P/TSX

    22,297.43
    +37.96 (+0.17%)
     

  • S&P 500

    5,186.46
    +5.72 (+0.11%)
     

  • DOW

    38,930.04
    +77.77 (+0.20%)
     

  • CAD/USD

    0.7307
    -0.0015 (-0.20%)
     

  • CRUDE OIL

    78.01
    -0.47 (-0.60%)
     

  • Bitcoin CAD

    86,706.56
    -647.27 (-0.74%)
     

  • CMC Crypto 200

    1,317.21
    -47.91 (-3.51%)
     

  • GOLD FUTURES

    2,326.80
    -4.40 (-0.19%)
     

  • RUSSELL 2000

    2,067.90
    +7.23 (+0.35%)
     

  • 10-Yr Bond

    4.4490
    -0.0400 (-0.89%)
     

  • NASDAQ

    16,335.63
    -13.61 (-0.08%)
     

  • VOLATILITY

    13.55
    +0.06 (+0.44%)
     

  • FTSE

    8,326.99
    +113.50 (+1.38%)
     

  • NIKKEI 225

    38,835.10
    +599.03 (+1.57%)
     

  • CAD/EUR

    0.6774
    -0.0018 (-0.26%)
     
MARKETS LIVE BLOG:

STOCKS OPEN HIGHER AS DISNEY EARNINGS SUPPORT

Disney's surprise streaming entertainment profit offset by weaker TV business

NervGen Pharma Extends the Expiry Date of Certain Stock Options

Newsfile Corp.
·1 min read

Vancouver, British Columbia--(Newsfile Corp. - June 2, 2023) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, announced a two-year extension of the expiry date of certain stock options (the "Options") granted to a consultant of the Company on April 23, 2021 and July 16, 2021, such that the terms of the Options shall be extended from three (3) years to five (5) years following the original grant dates, respectively. All other terms of the Options, including the exercise price, remain the same.

About NervGen

NervGen is a clinical stage biotech company dedicated to developing innovative treatments that enable the nervous system to repair itself following damage, whether due to injury or disease. The Company's initial target indications are spinal cord injury, Alzheimer's disease, and multiple sclerosis. For more information, go to www.nervgen.com.

ADVERTISEMENT

For further information, please contact:

Bill Adams, Chief Financial Officer
badams@nervgen.com

Huitt Tracey, Corporate Communications
htracey@nervgen.com
604.537.2094

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/168629